Source link : https://www.newshealth.biz/health-news/novel-crispr-cas9-based-promising-in-attr-cardiomyopathy/
CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to phase I data. A single IV infusion of nexiguran ziclumeran (nex-z), a therapy that targets production of TTR in the liver, was delivered to patients (n=36) with ATTR-CM, explained […]
Author : News Health
Publish date : 2024-11-17 22:26:23
Copyright for syndicated content belongs to the linked Source.
inHealth